PHASE I BORTEZOMIB AND RIXED-DOSE-RATE (FDR) GEMCITABINE

I 期硼替佐米和固定剂量率 (FDR) 吉西他滨

• 批准号: 7716650
• 负责人: Thehang Luu
• 金额: $ 3.24万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716650
• 关键词: Biological Assay; Bortezomib; Cells; Computer Retrieval of Information on Scientific Projects Database; Dose-Rate; Drug Delivery Systems; Funding; Grant; Human; Immunohistochemistry; Institution; Molecular; Pattern; Phase; Polymerase Chain Reaction; RRM2 gene; Research; Research Personnel; Resources; Signal Transduction; Source; Time; United States National Institutes of Health; cancer cell; gemcitabine; ribonucleotide reductase M2

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The molecular study will focus on the following: Investigate the mechanisms(s) underlying sumoylation and its steady-state level. 1. Evaluate the correlation between expression level of drug target such as RRM2 and SUMO-1 in human cancer cells; 2. Characterize the change(s) in sumoylation patterns elicited by treatment; 3. Assess differential signal transduction in Bortezomib compared to untreated cells using Real-Time PCR or immunohistochemistry assays.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 分子研究将集中在以下方面： 研究sumoylation及其稳态水平的机制。 1.评价RRM 2、SUMO-1等药物靶点在人癌细胞中表达水平的相关性; 2.表征处理引起的sumoylation模式的变化; 3.使用实时PCR或免疫组织化学测定评估Bortez与未处理细胞相比的差异信号转导。